» Articles » PMID: 22297732

Bone Mineral Density by DXA and HR PQCT Can Discriminate Fracture Status in Men and Women with Stages 3 to 5 Chronic Kidney Disease

Overview
Journal Osteoporos Int
Date 2012 Feb 3
PMID 22297732
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Fractures are common in chronic kidney disease (CKD). We determined if bone mineral density testing by dual energy X-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HR pQCT) could discriminate fracture status in CKD patients. Both tests were able to discriminate fracture status. Further, the addition of HR pQCT measurements to DXA measurements did not improve fracture discrimination.

Introduction: The optimal method to identify individuals with CKD at high fracture risk is unknown.

Methods: We determined if bone mineral density (BMD) by DXA and HR pQCT could discriminate fracture status in 211 adult men and women with stages 3 to 5 CKD, attending predialysis clinics in Toronto Canada, using logistic regression. Results are expressed as the odds ratio (OR) of fracture (prevalent vertebral and/or low trauma since age 40 years) per standard deviation decrease in the predictor adjusted for age, weight, sex, and CKD stage. We constructed receiver operating characteristic curves to examine the discriminative ability of BMD measures for fracture.

Results: Most participants were Caucasian men with a mean age of 63.3 ± 15.5 years. There were 77 fractures in 74 participants. Decreases in BMD were associated with increased fracture risk: OR = 1.56 (95% confidence interval (CI), 1.41 to 1.71) for BMD by DXA at the ultradistal radius, and OR = 1.24 (95% CI, 1.12 to 1.36) for cortical area by HR pQCT. Further, while both tests were able to discriminate fracture status, the addition of HR pQCT measures to BMD by DXA did not improve fracture discrimination ability.

Conclusions: Among CKD patients not yet requiring renal replacement therapy, BMD by DXA is able to discriminate fracture status.

Citing Articles

The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease.

Aleksova J, Ebeling P, Elder G Nat Rev Endocrinol. 2025; .

PMID: 39820573 DOI: 10.1038/s41574-024-01083-8.


Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview.

Izzo C, Secondulfo C, Bilancio G, Visco V, Virtuoso N, Migliarino S Life (Basel). 2024; 14(3).

PMID: 38541742 PMC: 10971621. DOI: 10.3390/life14030418.


Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.

Cipriani C, Lauriero G, Tripepi G, Ferrari S, Bover J, Ravera M J Clin Med. 2023; 12(23).

PMID: 38068310 PMC: 10707671. DOI: 10.3390/jcm12237260.


Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.

Fusaro M, Pereira L, Bover J J Clin Med. 2023; 12(19).

PMID: 37834950 PMC: 10573159. DOI: 10.3390/jcm12196306.


Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial.

Levy-Schousboe K, Marckmann P, Frimodt-Moller M, Peters C, Kjaergaard K, Jensen J Nephrol Dial Transplant. 2022; 38(10):2131-2142.

PMID: 36460034 PMC: 10539208. DOI: 10.1093/ndt/gfac315.


References
1.
Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

2.
Jamal S, Chase C, Goh Y, Richardson R, Hawker G . Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis. 2002; 39(4):843-9. DOI: 10.1053/ajkd.2002.32006. View

3.
Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S . Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone. 1996; 19(5):549-55. DOI: 10.1016/s8756-3282(96)00246-3. View

4.
Dolgos S, Hartmann A, Bonsnes S, Ueland T, Isaksen G, Godang K . Determinants of bone mass in end-stage renal failure patients at the time of kidney transplantation. Clin Transplant. 2008; 22(4):462-8. DOI: 10.1111/j.1399-0012.2008.00810.x. View

5.
Miller P, Roux C, Boonen S, Barton I, Dunlap L, Burgio D . Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20(12):2105-15. DOI: 10.1359/JBMR.050817. View